Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals — Technical Presentation (September 2019)

17 slides from Avadel Pharmaceuticals's technical presentation, Sep 25, 2019

  1. Slide 1: Pharmacokinetics of once-nightly controlled-release sodium oxybate (FT218): Four Phase 1 Studies

    The Pharmacokinetics of once - nightly controlled - release sodium oxybate (FT218): Overview of results from four Phase 1 Studies Dr. Michael Thorpy Director of the Sleep - Wake Disorders Center at the Montefiore Medical Center 1

  2. Slide 2: Safe Harbor

    Safe Harbor 2 This presentation may include forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expression

  3. Slide 3: Introduction

    Introduction • Sodium oxybate is an effective treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy • The approved effective doses of sodium oxybate are 6, 7.5 and 9 g per night, divided in two doses – the first taken at bedtime and the second 2.5 – 4 hours later. • FT

  4. Slide 4: FT-PK Data

    FT - 218 PK Data Four crossover, single - dose pharmacokinetic studies were conducted in healthy volunteers • Pilot PK Study • Dose Proportionality Study • Relative Bioavailability Study • Food Effect Study 4

  5. Slide 5: Pilot PK Study

    Pilot PK Study Crossover Study comparing Once - Nightly FT218 4.5 g v. Twice - Nightly Sodium Oxybate IR 4.5 g (2.25 + 2.25) 5

  6. Slide 6: Crossover Study of Three Formulations of Once-Nightly FT218 vs Twice-Nightly Sodium Oxybate IR

    0 20 40 60 80 0 2 4 6 8 10 12 Type 1 Type 2 Type 3 Twice - nightly sodium oxybate Crossover Study of Three Formulations of Once - Nightly (FT218) 4.5 g vs. Twice - Nightly Sodium Oxybate IR 4.5 g (2.25+ 2.25): N=16 x Similar overall exposure (AUC) to twice nightly dosing x Lower overall peak concent

  7. Slide 7: Exploratory Endpoints: Leeds Sleep Evaluation Questionnaire

    Exploratory Endpoints: Leeds Sleep Evaluation Questionnaire – No formal Statistical Analysis 7

  8. Slide 8: Safety Profile Comparable For Single Dose Administration

    Safety Profile Comparable For Single Dose Administration: All Adverse Events (AEs) mild to moderate, No SAEs, No discontinuation Due to AE 8

  9. Slide 9: Dose Proportionality Study

    Dose Proportionality Study Three - Period Single Ascending Dose Study comparing Once - Nightly FT218 4.5g, 7.5g and 9g dosages 9

  10. Slide 10: Three-Period Single Ascending Dose Study

    Three - Period Single Ascending Dose Study (n=20): Subjects received single doses of 4.5, 7.5 and 9 g with at least 7 day washout between doses • For the 3 doses, mean pharmacokinetics exhibited similar overall profiles with median Tmax between 1.5 and 2 hours • FT218 was dose proportional for Cmax

  11. Slide 11: Relative Bioavailability Study

    Relative Bioavailability study at 6 g Two - Period Crossover Study comparing Once - Nightly FT218 6 g v. Twice - Nightly Sodium Oxybate IR 6 g (3+3) 11

  12. Slide 12: Randomized Crossover Design of FT218 6 g vs Twice-Nightly Sodium Oxybate IR

    Randomized, crossover, two period, two sequences design of FT218 6 g or twice - nightly sodium oxybate IR 6 g (3 + 3) MAIN ANALYSIS: • AUC of FT218 meets bioequivalence criteria compared to AUC of Twice - nightly SO IR • Cmax of FT218 is lower than overall Cmax of Twice - nightly SO IR POST - HOC AN

  13. Slide 13: Safety Profile

    Safety Profile • All AEs were mild or moderate in severity • There were no SAEs reported • 1 subject dropped out in each treatment group due to AE (Nausea for FT218 and influenza for Twice nightly sodium oxybate) • In general, the safety profile appeared comparable between the two groups 13 Preferre

  14. Slide 14: Food-Effect Study

    Food - effect study Two - Period Crossover Study comparing Once - Nightly (FT218) 6 g in Fed and Fasted states 14

  15. Slide 15: Randomized Crossover Design at 6 g: Fed vs Fasted

    Randomized, Crossover, two - period, two - sequences design (N=16) at 6 g: Fed (30 min after high - fat breakfast) vs. Fasted (10 - hour Overnight Fast) State • Cmax in the Fed state is below Cmax in the Fasted state (66.7%) • AUC in the Fed state is slightly lower than AUC in the Fasted state (PE 8

  16. Slide 16: Safety Profile

    Safety Profile • All AEs were mild or moderate in severity with higher incidences in fasted vs. fed state • There were no SAEs • 1 subject discontinued due to vomiting after receiving FT218 in the fasted state 16

  17. Slide 17: Conclusions

    Conclusions • Once - nightly FT218 at 4.5 and 6 g demonstrated: • a lower overall Cmax and equivalent exposure to twice - nightly sodium oxybate IR • similar morning plasma levels (C8h) and variability to twice - nightly sodium oxybate IR • For FT218, Cmax was dose proportional and AUC was slightly

Avadel Pharmaceuticals — Technical Presentation (September 2019) on 6ix